Globally, the tightening of environmental protection policies has become an irreversible trend. The European Union's Circular Economy Action Plan and China's "Dual Carbon" goals have raised clear requirements for the environmental friendliness of pharmaceutical packaging materials, emphasizing the need to reduce the environmental footprint of non-degradable plastic packaging and promote the development of green, sustainable alternatives. Meanwhile, the rapid advancement of precision medicine has driven the upgrading of pharmaceutical formulations-emerging dosage forms such as personalized medication, targeted release, and cell therapy have put forward higher functional demands for capsules, which are no longer limited to the basic functions of drug encapsulation and delivery, but also need to meet requirements such as controlled release rate, site-specific targeting, biocompatibility with active ingredients, and adaptability to complex clinical scenarios.
Against this backdrop, traditional capsule materials (such as gelatin and synthetic non-degradable polymers) can no longer fully satisfy the dual demands of environmental protection and advanced pharmaceutical development. Gelatin capsules face limitations in religious adaptability and animal-derived safety risks, while non-degradable synthetic polymer capsules are prone to accumulate in the environment, causing microplastic pollution. Thus, the R&D of degradable and functional capsule materials has become a core focus of the global pharmaceutical packaging industry, triggering a wave of technological innovations.
R&D Breakthroughs and Impacts
1. Marine Polysaccharide-Based Degradable Materials: From Laboratory to Pilot Scale
Marine polysaccharides represented by alginate and chitosan have become the mainstream direction of degradable capsule materials due to their excellent biocompatibility, natural degradability, and unique functional properties. Recent studies have achieved key progress in material modification, composite application, and process optimization, pushing these materials from laboratory research to pilot scale production.
Alginate, extracted from brown algae, forms a thermally stable three-dimensional network structure through cross-linking with divalent cations (such as calcium ions). Its pH sensitivity makes it ideal for probiotic encapsulation-alginate-based capsules can resist dissolution in the low-pH gastric environment to protect probiotics, while the ionic cross-linking structure breaks down in the neutral-intestinal environment to release active ingredients. Recent technological improvements have focused on optimizing the mannuronic acid (M)/guluronic acid (G) ratio of alginate, and composite wall materials prepared by blending with carrageenan or agar have significantly improved mechanical strength and controlled release performance, solving the problem of poor stability of single alginate capsules in the gastrointestinal tract. Currently, such composite alginate capsules have entered pilot scale trials for oral probiotic and enzyme preparations, with encapsulation efficiency exceeding 90% and probiotic survival rate in gastric fluid increased by 3-5 times compared to traditional formulations.
Chitosan, derived from the deacetylation of chitin in crustaceans, is the only natural cationic polysaccharide with good biodegradability and bioadhesiveness. It can form strong polyelectrolyte complexes with anionic polymers such as alginate, further enhancing the stability of capsules in low-pH environments. Recent research has focused on modifying chitosan to reduce its cytotoxicity and improve solubility-quaternized chitosan derivatives have shown excellent antibacterial activity while maintaining biocompatibility, making them suitable for encapsulating antibacterial drugs and reducing the risk of intestinal flora disturbance. Pilot scale production lines for chitosan-based capsules have been established in Southeast Asia and Europe, mainly used for targeted delivery of anti-inflammatory drugs in the colon, achieving sustained release for 12-24 hours and improving therapeutic efficacy while reducing side effects.
In addition to alginate and chitosan, marine polysaccharides such as pullulan and hyaluronic acid have also been widely explored. Pullulan, a neutral extracellular polysaccharide, has good film-forming properties and can act as a prebiotic to selectively promote probiotic growth, showing great potential in synbiotic preparations. These marine polysaccharide-based materials not only meet environmental protection requirements (fully degraded into water and carbon dioxide in natural environments within 3-6 months) but also realize functional integration of "protection-delivery-nutrition", opening up new paths for green pharmaceutical formulations.
2. 3D-Printed Customized Hollow Capsules: Laboratory Verification and Technological Breakthroughs
3D printing technology has broken the process limitations of traditional "dip-coating molding" in capsule production, realizing the customized preparation of hollow capsules with arbitrary shapes, adjustable wall thickness, and personalized functions, and has successfully passed laboratory verification in recent years.
Researchers have adopted fused deposition modeling (FDM) and microfluidic 3D printing technologies to prepare hollow capsules using degradable materials such as polyvinyl alcohol (PVA), polylactic acid (PLA), and modified alginate. By optimizing printing parameters (extrusion temperature, printing speed, material flow rate, and nozzle diameter), capsules with dimensions matching commercial hard gelatin capsules (size 0-2) have been successfully fabricated, with wall thickness adjustable between 0.2-0.9 mm. In vitro dissolution tests show that PVA-based 3D-printed capsules can achieve delayed release profiles by adjusting wall thickness-capsules with a wall thickness of 0.6 mm have a disintegration time 2-3 times longer than commercial gelatin capsules, meeting the demand for sustained-release formulations. More importantly, 3D printing enables the preparation of special-shaped capsules (such as oval, triangular, and multi-compartment structures) that cannot be produced by traditional processes. Multi-compartment capsules can co-encapsulate incompatible drugs or drugs with different release rhythms, realizing sequential release and improving the synergy of combined medication.
A major breakthrough in microfluidic 3D printing technology is the preparation of core-shell structured hydrogel capsules. In December 2025, two landmark studies published in Science independently developed semipermeable core-shell hydrogel capsules based on liquid-liquid phase separation (LLPS) principle. The CAGEs (Capsules with Amphiphilic Gel Envelopes) developed by Harvard University's Allon M. Klein team use amphiphilic block copolymer F127DA as the shell material, forming a foam-like porous structure with a pore size of 10-50 nm after cross-linking. This structure allows free diffusion of reagents such as DNA polymerase while retaining nucleic acids above 300 bp, realizing long-term culture of living cells and multi-step genomic analysis in a single capsule. The SPCs (Semipermeable Capsules) developed by Vilnius University's Linas Mazutis team use GelMA and dextran as materials, which can be degraded by collagenase to release living cells with a survival rate exceeding 90%, solving key problems in clinical sample single-cell analysis such as fragile cell capture and RNA degradation.
3. Emerging Functional Degradable Materials: Photodegradable and Intelligent Response Types
Recent research has also focused on the development of functional degradable capsules with stimuli-responsive degradation properties, expanding their application scenarios beyond pharmaceuticals to cosmetics, agriculture, and other fields. Japanese researchers from Osaka Metropolitan University have developed biodegradable polymer capsules using plant-derived and lipid-based molecules through interfacial photocycloaddition polymerization. These capsules form a polymer shell through light-driven reactions without external catalysts, maintaining stability for over a year under normal conditions while degrading rapidly under 254 nm ultraviolet light or alkaline water, leaving no environmental residues. This technology provides a sustainable alternative to traditional non-degradable microcapsules in cosmetics and agrochemicals, avoiding microplastic pollution.
Comprehensive Industry Impacts
These R&D breakthroughs have profoundly reshaped the development pattern of the hollow capsule industry. Technically, they have broken the long-term monopoly of traditional dip-coating molding processes, establishing a new technical route of "material customization + process personalization" and enabling the production of special capsules with controlled release, targeted delivery, and multi-functional integration. In terms of application, degradable and functional capsules provide new carriers for high-end formulations such as single-cell therapy, personalized medication, and synbiotics, accelerating the transformation of precision medicine from basic research to clinical application. Environmentally, they respond to global carbon neutrality goals, promoting the upgrading of the pharmaceutical packaging industry towards greenization and sustainability.
Currently, although these technologies still face challenges such as high production costs, scale-up difficulties, and unclear regulatory standards, continuous breakthroughs in material science and process engineering are expected to promote their industrialization in the next 3-5 years. It will further drive the industry to move towards a high-end, intelligent, and eco-friendly direction, bringing revolutionary changes to drug delivery systems and pharmaceutical packaging.
